Cardiometabolic News and Research

RSS

Orexigen presents data from Contrave trial at 29th Annual Scientific Meeting of The Obesity Society

Orexigen Therapeutics, Inc., today announced that Contrave (naltrexone SR/bupropion SR) data will be presented in one oral and multiple poster presentations at the 29th Annual Scientific Meeting of The Obesity Society on October 3, 2011 in Orlando, FL.

4 Oct 2011

Santaris Pharma to report new clinical data from miravirsen Phase 2a study on HCV

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA and mRNA-targeted therapies, today announced the Company will report new clinical data results from the miravirsen Phase 2a proof-of-concept study to treat patients infected with the Hepatitis C virus (HCV) in a late-breaking oral presentation session at the American Association for the Study of Liver Diseases (AASLD) 2011 annual meeting.

4 Oct 2011

New test to better predict heart attack risk in women

The biggest killer of women over the age of 50 is heart disease. By age 65 women have the same heart attack or stroke risk as men and a greater risk of dying from either. To help better predict heart attack risk in these women, Atherotech Diagnostics Lab has developed a new and better way to test for heart disease risk. The new test will soon be available exclusively through Atherotech Diagnostics Lab.

26 Aug 2011

Parkinson's important protein linked with fat metabolism

National Institutes of Health researchers have found that Parkin, an important protein linked with some cases of early-onset Parkinson's disease, regulates how cells in our bodies take up and process dietary fats.

26 Aug 2011

Study links low vitamin D with early menstruation in young girls

A study links low vitamin D in young girls with early menstruation, which is a risk factor for a host of health problems for teen girls as well as women later in life.

12 Aug 2011

Patients receive inadequate medical monitoring for prescribed drugs in psychiatric settings

New research from the University of Leicester demonstrates that psychiatrists are not offering adequate checks for metabolic complications that are common in patients with mental ill health - especially those prescribed antipsychotic medication.

10 Aug 2011

Merck Serono announces recipients of second Grant for Fertility Innovation

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announces the recipients of its second Grant for Fertility Innovation.

8 Jul 2011

Short-term lowering of PreDx DRS may reduce risk of developing diabetes

Data presented today from an analysis of samples from the European Diabetes Prevention Study (EDIPS) showed that the PreDx Diabetes Risk Score (DRS) is lowered by lifestyle intervention, which correlates to a reduction in the risk that patients will develop diabetes over time.

27 Jun 2011

InVasc commences INV-144 Phase IIa trial in chronic kidney disease

InVasc Therapeutics, Inc., announced today that it has initiated a Phase IIa, proof of concept (POC), clinical trial with INV-144, a combination drug of losartan with alpha Lipoic Acid (ALA), to slow the progression of chronic kidney disease (CKD) in hypertensive diabetic patients.

24 Jun 2011

Patient enrollment complete in cilengitide Phase III study against glioblastoma

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that patient enrollment in the global pivotal Phase III clinical study CENTRIC has been completed.

9 Jun 2011

Santaris Pharma advances SPC4955 into Phase 1 trial for high cholesterol treatment

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that it has advanced a second drug from its cardiometabolic program, SPC4955 into Phase 1 clinical trials, for the treatment of high cholesterol.

11 May 2011

Coronary artery disease patients with high BMI may face higher risk of death

One of the largest studies of its kind has found that people with coronary artery disease who have even a modest beer belly or muffin top are at higher risk for death than people whose fat collects elsewhere. The effect was observed even in patients with a normal Body Mass Index.

3 May 2011

Grapefruit can help reduce weight in obese adults

One-hundred percent grapefruit juice – a dieter's friend? A new study, published in Nutrition & Metabolism, concluded that enjoying a pre-meal snack of grapefruit, grapefruit juice or water as part of a reduced-calorie diet can be part of an effective weight loss strategy for obese adults.

28 Apr 2011

Investigational drug effective for patients with obesity

An investigational combination of drugs already approved to treat obesity, migraine and epilepsy produced up to a 10 percent weight loss in obese individuals participating in a one-year clinical trial, according to researchers at Duke University Medical Center.

11 Apr 2011

GI Dynamics announces positive results from EndoBarrier studies against type 2 diabetes

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, announced today new results from three studies that demonstrate the positive effects of the EndoBarrier Gastrointestinal Liner on type 2 diabetes, weight loss and other metabolic factors.

30 Mar 2011

Merck submits Erbitux indication extension to EMA for NSCLC treatment

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it has submitted an indication extension to the European Medicines Agency for the approval of Erbitux in combination with standard 1st line platinum-based chemotherapy in patients with advanced or metastatic non-small cell lung cancer with high epidermal growth factor receptor expression.

30 Mar 2011

Xenon founder receives Canada Wightman Award for leadership in medical science

Dr. Michael Hayden, a Xenon founder and Chief Scientific Officer, has received the Canada Gairdner Wightman Award for leadership in medical science in Canada.

23 Mar 2011

NYC expands YMCA's Diabetes Prevention Program to help adults avoid disease consequences

The YMCA of Greater New York today announced the New York City expansion of the YMCA's Diabetes Prevention Program, a 16-session group behavior change class that helps people at high risk for developing type 2 diabetes prevent the disease through healthy eating, increased activity and other positive lifestyle changes.

22 Mar 2011

FDA accepts Arisaph's ARI-3037MO IND for phase I human clinical trial

Arisaph Pharmaceuticals, Inc., a privately held drug discovery biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted the Company's recently submitted Investigational New Drug application to evaluate ARI-3037MO in a phase I human clinical trial in healthy volunteers.